
Disclosure: Zepp Health Corporation has paid FRC a fee for research coverage and distribution of reports. See last page for other important disclosures, rating, and risk definitions.
Subscribe for free to get exclusive insights and fair value data.
⭐️ FRC's Top Pick ⭐️
Price Performance (1-year)

Unit Sales & Other Key Metrics
Q1 shipments of self-branded products were up 25% YoY, aligning with our estimate

Source: FRC / Company
In line with industry standards, Zepp retains 70% of the retail price of its products as revenue, while retailers and distributors keep the remaining 30%.
Zepp does not disclose segmented results:
Revenue from these products increased 10% YoY, also consistent with our estimate. The company did not manufacture any products for Xiaomi in the quarter; as a result, overall revenue declined 4% YoY, missing our estimate by 2%

Gross margins held steady at 37%, missing our estimate by 1 pp, but remain well above the Consumer Electronics sector average of 25%. Zepp spent 17% of revenue on sales/marketing, while Apple and other majors typically spend <5%
Operating expenses were up 7% YoY, and were 5% higher than our estimate, primarily due to increased marketing expenses. As a result of lower revenue, EPS declined from -$0.06 to -$0.08, 9% below our estimate
Working capital, and investments, net of long-term debt was $179M vs the current MCAP of just $38M, implying that ZEPP is trading well below liquid assets
FRC Projections and Valuation
According to Research and Markets, the global smart wearables market should grow from $109B in 2023, to $304B by 2029, reflecting a CAGR of 19%.
Zepp’s products accounted for 2.8% of global smartwatch shipments in 2024. It is estimated that global smartwatch shipments will increase 2% in 2025

Historically, Zepp's revenue growth rate has averaged 1.4x the global growth rate. As Q1 operating expenses were higher than expected, we are lowering our 2025 and 2026 EPS estimates
As a result, our DCF valuation decreased from $11.50 to $10.11/share
Comparables Valuation

ZEPP remains the most undervalued stock on our list of comparables, trading at 0.04x forward revenue vs the sector average of 2.12x (previously 2.27x)
Applying 2.12x to our 2025 revenue forecast for Zepp, we arrived at a comparables valuation of $14.52/share (previously $16.22/share
We are reiterating our BUY rating, and adjusting our fair value estimate from $13.87 to $12.32/share (the average of our DCF and comparables valuations). Despite a modest EPS miss due to higher marketing spend, Zepp delivered solid revenue growth and maintained its position among the top global smartwatch makers. Tariff-related risks remain, but upcoming product launches and a diversified manufacturing footprint should help Zepp sustain organic growth, and limit downside exposure.
Risks
We are maintaining our risk rating of 3 (Average)
We believe the company is exposed to the following key risks (not exhaustive):
Appendix

